RTTNews BiotechQwen · 实盘不做把握 3/10不做原因:已被定价
北京时间·🕒 发布 00:08:22·⟳ 抓取 00:15:21 +6m59s·⚡ 决策 08-27 00:18:14 +2m53s·61.7 天前
FDA批准Revolution Medicines的first-in-class RAS抑制剂Rasonque（daraxonrasib）用于经治转移性胰腺腺癌
FDA批准是高度预期的程序性落地（突破性疗法+优先审评+孤儿药+5月已启动扩大可及性），股价在批准前20日已涨17%至52周高附近，今日盘中先跌后回（低见$198.94），确认市场已按'买预期卖事实'消化。市值$457亿，获批本身不构成新增预期差。自家案例库同日已有8条以上相同事件的AVOID决策。
📄 原文RTTNews Biotech↗ 原文
Revolution Medicines Wins FDA Approval For Rasonque In Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), a RAS inhibitor developed by Revolution M…
不做 Revolution Medicines（RVMD.US）
FDA批准是高度预期的程序性落地（突破性疗法+优先审评+孤儿药+5月扩大可及性），股价已提前数周涨至52周高附近（20日+16.91%），今日盘中先跌后回确认见光死，市值$457亿无新增预期差，无剩余短线edge。自家案例库同日已有8条以上相同事件AVOID。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
FDA批准Rasonque是确定性极高的程序性落地：该药获突破性疗法认定、优先审评、孤儿药认定，5月已获扩大可及性许可，市场早已定价获批。RVMD在批准前20个交易日上涨16.91%，当前价$212.47距52周高$220.34仅4%。今日盘中一度跌至$198.94（-5.9%），随后回升至$212，呈现典型'见光死'后企稳模式。市值已达$457亿，获批消除了最后的监管不确定性但不创造新增预期差。经验教训'confidence-vs-expectation-gap'明确警示：名义大但已被预期的事件不应给高把握度。结论：无剩余edge，不做。
🔎 新鲜度:最早出现 2026-08-26 · 扩散 high · price-in 风险 high ↗
消息传播链
- FDA正式批准，比PDUFA提前6.5个月；批准本身是程序性落地而非意外市场反应:RVMD盘中一度跌至$198.94（-5.9%），随后回升至$212附近，成交量仅为20日均量的0.5倍，无追涨动力
反向证据
- 做多前查反向 · 来源 stock_quote · 日期 2026-08-26 · 影响 invalidates
股价在批准前20日涨16.91%至52周高附近，今日盘中低见$198.94（-5.9%）后回升，量比仅0.5x，确认市场已提前定价且无追涨意愿
检索:RVMD FDA approval sell the news price reaction anticipation
先例如何影响了这次决策
对本次决策的影响:先例缺失不改变结论，因为价格行为本身已确认price-in
方向:无法完成外部先例统计（web_search不可用），但基于价格行为和经验判断，高度预期的FDA批准通常呈现'买预期卖事实'模式
涨幅量级:无可用先例数据
形态:今日盘中先跌后回的模式与'见光死'一致
工具调用 · 历史记录,结果未知(6 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- stock_quote · 结果未知
- search_case_library · 结果未知
- web_search · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,338 字
The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), a RAS inhibitor developed by Revolution Medicines, Inc. (RVMD), for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Rasonque is a once-daily tablet designed to target multiple forms of RAS, a key driver of tumor growth in pancreatic adenocarcinoma.
The approval was supported by a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma.
In the trial, Rasonque improved median overall survival to 13.2 months compared with 6.7 months for standard chemotherapy.
The FDA said the approval was granted 6.5 months before the user fee deadline, reflecting an accelerated review for a serious and life-threatening cancer.
Rasonque received FDA Breakthrough Therapy and Orphan Drug designations and was granted Priority Review for the indication.
The application was also reviewed under the Commissioner's National Priority Voucher pilot program, which is intended to accelerate the review of therapies addressing national public health priorities.
In May, the FDA issued a "safe to proceed" letter allowing Revolution Medicines to initiate an expanded access treatment protocol for Rasonque before approval under applicable FDA regulations.
The most common side effects of Rasonque include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite and hemorrhage.
The approval marks a significant regulatory milestone for Revolution Medicines and provides a new targeted treatment option for patients with metastatic pancreatic adenocarcinoma, a cancer associated with high mortality and limited treatment options.
RVMD has traded between $35.64 and $220.34 over the past year.
Currently, the stock is trading at $213.35, up 0.94%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
Rasonque is a once-daily tablet designed to target multiple forms of RAS, a key driver of tumor growth in pancreatic adenocarcinoma.
The approval was supported by a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma.
In the trial, Rasonque improved median overall survival to 13.2 months compared with 6.7 months for standard chemotherapy.
The FDA said the approval was granted 6.5 months before the user fee deadline, reflecting an accelerated review for a serious and life-threatening cancer.
Rasonque received FDA Breakthrough Therapy and Orphan Drug designations and was granted Priority Review for the indication.
The application was also reviewed under the Commissioner's National Priority Voucher pilot program, which is intended to accelerate the review of therapies addressing national public health priorities.
In May, the FDA issued a "safe to proceed" letter allowing Revolution Medicines to initiate an expanded access treatment protocol for Rasonque before approval under applicable FDA regulations.
The most common side effects of Rasonque include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite and hemorrhage.
The approval marks a significant regulatory milestone for Revolution Medicines and provides a new targeted treatment option for patients with metastatic pancreatic adenocarcinoma, a cancer associated with high mortality and limited treatment options.
RVMD has traded between $35.64 and $220.34 over the past year.
Currently, the stock is trading at $213.35, up 0.94%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。